+7 993 357-99-03
En
Ru
Developing immunobiological products for healthy and safe future
CJSC "RBT" — the developer of own "Betusphere" platform for development of combined adjuvant systems for vaccines with a high safety profile
20+
team members
29+
completed biotech projects
11+
years on the vaccine market
40+
years of experience in R&D of biotech products

The "BetuSphere" platform offers extensive opportunities for the portfolio development and creation of new vaccines

About
The "RBT" company was established in 2011 for R&D projects in the field of innovative medicines. By combining research experience with successful practical implementation, "RBT" develops challenging projects in the area of biopharmaceuticals.

In 2021, "Artgen Biotech" invested in the development of "RBT" biotechnology platform and creation a number of vaccine drugs against infectious diseases.

In June 2022, the company was assigned the status of a participant in the project for the creation and maintenance of the Skolkovo Innovation Center.
Welcome our team with the successful experience in launching vaccines on the market, attracting investments and biotech IPOs.
  • Igor Krasilnikov
    CEO
    Ph.D, Dr.Sci, Prof., International WHO advisor in vaccine development (Initiative for Vaccine Research program)
  • Artur Isaev
    Strategist, anchor investor
    Founder of "Artgen Biotech", "Gemabank" — the largest russian bank of umbilical cord blood stem cells
  • Anna Vakhrusheva
    CEO "Betuvax", MD, PhD
    Developer of 10+ new drugs
    Winner in the nomination "Technological Breakthrough-2021"
  • Taras Ivanishin

    Executive Director

    5+ years in biotech investments. Faculty of Chemistry, Lomonosov Moscow State University, RANEPA under the President of the Russian Federation
  • Alexander Belenkov
    Production Director
    More than 5 years in organization and management of biotechnological productions, SPbNIIVS, R-Pharm, ZIO-Zdorovye
  • Pavel Pogodin
    Legal Director
    >10 years in senior management positions in the public and biotech sectors
  • Irina Tsymbarevich
    CTO
    PhD, UZH (imMed), 7+ years of experience in pharmaceutical R&D and technology development
  • Alexander Kudryavtsev
    CTO "Betuvax", co-author of the technology
    Graduate of the Postgraduate Program of the Department of Bioengineering, Faculty of Biology, Lomonosov Moscow State University
  • Mark Kolotov
    Development Director
    Ex-Regional Director of GSK Vaccines (UK), Regional Manager of Boehringer Ingelheim (Germany) and Key Account Director of Aventis Pasteur (France)
  • Milana Djonovic
    Scientific Advisor
    Experience in genotherapeutic drug development, patenting and bioinformatics
  • Maria Sukhova
    Research Associate
    Faculty of Biotechnology, Lomonosov Moscow State University
  • Polina Safarova
    Project Manager
    Faculty of Medicine and Biology, N.I. Pirogov RNIMU
  • Valeria Kabina
    Project Manager
    MFin. More than 5 years in the financial sphere. RANEPA under the President of the Russian Federation
Contacts
CJSC (Closed Joint-Stock Company)
"Biotechnology Developments"
(CJSC RBT)

TIN: 9729341365
RRC: 772901001
PSRN: 1237700160070

Address: 96, pr-kt Vernadskogo "Moscow Center for Healthcare and Innovations"
Phone: +7(993)357-99-03
E-mail: info@rbiotech.ru
By pressing button you confirm your consent to the processing of your personal data and the Confidentiality Policy

Research is carried out with the grant support of the Skolkovo Foundation.

© "Biotechnology Developments", 2024